ProCE Banner Activity

Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022

Text Module

Examiner les points de vue et les idées des experts sur les données les plus pertinentes sur le plan clinique pour le traitement de la leucémie lymphoïde chronique et du lymphome à cellules du manteau présentées lors des réunions annuelles de 2022 de l’ASCO, de l’EHA, de la Pan Pacific Lymphoma Conference, de l’ESMO et de la SOHO.

Released: January 13, 2023

Expiration: January 12, 2024

Share

Faculty

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Lilly

Faculty Disclosure

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Matthew S. Davids, MD, MMSc:consultant: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono Pharmaceuticals, Research to Practice, Takeda, TG Therapeutics, Verastem, Zentalis; researcher: AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem.

Toby Eyre, MBChB, MD: advisor: AbbVie, AstraZeneca, Incyte, Janssen, Kite/Gilead, Lilly, Loxo, Roche.

Christopher R. Flowers, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol-Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; researcher (paid to institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Brad S. Kahl, MD:consultant: AbbVie, Acerta Pharma, ADCT Therapeutics, AstraZeneca, Celgene, Genentech, MEI, Morphosys, Pharmacyclics, Roche, TG Therapeutics.

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, Acerta, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Genmab, Gilead, Incyte, Janssen, Kite, Lilly, Morphosys, Pharmacyclics.

Anthony Mato, MD, MSCE:consultant: AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.

Julie M. Vose, MD, MBA:consultant/advisor: AbbVie, AstraZeneca, Caribou, Daiichi Sankyo, Genentech, Lilly, MEI Pharma, MorphoSys, Pharmacyclics.